Worth reading
48Recurring
Scored from 4 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
254500
Shares (2,545 share subscription rights, 100 shares per right)Wording
Definitive
How definitive the wording is.Details of issuance or disposal
Issuance of share subscription rights as stock options (Nomura Micro Science Co.,Ltd. Ninth Series Share Subscription Rights)
発行・処分する株式数
254,500 common shares (2,545 share subscription rights, 100 shares per right)
Intended allottee
Name Executive officers and employees of the Company / Number of Employees 415 people / Number allocated 2,545 rights
Terms of the stock acquisition rights
Exercise price
The higher of 1.05 times the average closing price for the month preceding the month containing the allotment date or the closing price on the allotment date. Adjustment provisions apply in the event of a share split, share consolidation or similar event. The floor is Not disclosed.
Exercise period
Start Date 21 August 2028 / End date 18 August 2033
Number of Stock Acquisition Rights
Total number issued 2,545 rights (planned allotment; the number may decrease if applications are not made or for other reasons) / Unexercised balance Not disclosed
Reason for acquisition without consideration
If a proposal concerning a merger, company split, share exchange, share transfer, conversion into a company with transfer restrictions or similar transaction is approved at a shareholders meeting, or by resolution of the Board of Directors where a shareholders meeting resolution is not required, the Company may acquire the share subscription rights without consideration on a date designated by the Company's Board of Directors.
Conditions on transfer restrictions
Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.
Conditions for lifting transfer restrictions
The transfer, pledging or any other disposition of the share subscription rights is prohibited. As a general rule, the holder must hold a position as a director, audit & supervisory board member, executive officer or employee of the Company or one of its subsidiaries at the time of exercise.
Categories and Number of Persons Covered
The Company's executive officers and employees: 415 people, 2,545 rights
Intended allottee's holding policy
The transfer, pledging or any other disposition of the share subscription rights is prohibited.
Basis for determining the amount to be paid
The exercise price will be the higher of 1.05 times the average closing price for each trading day in the month preceding the month containing the allotment date or the closing price on the allotment date. The specific share price and exercise price have not yet been determined.
Procedures under the Corporate Code of Conduct
Resolved at the Board of Directors meeting held on 15 July 2026. Not disclosed whether an opinion was obtained from an independent third party or whether shareholder intentions were confirmed.
| Item | Details |
|---|---|
| Type of issuance or disposal | Issuance of share subscription rights as stock options (Nomura Micro Science Co.,Ltd. Ninth Series Share Subscription Rights) |
| Number of shares to be issued or disposed of | 254,500 common shares (2,545 share subscription rights, 100 shares per right) |
| Intended allottee | Name Executive officers and employees of the Company / Number of Employees 415 people / Number allocated 2,545 rights |
| Intended allottee's holding policy | The transfer, pledging or any other disposition of the share subscription rights is prohibited. |
| Basis for determining the amount to be paid | The exercise price will be the higher of 1.05 times the average closing price for each trading day in the month preceding the month containing the allotment date or the closing price on the allotment date. The specific share price and exercise price have not yet been determined. |
| Exercise price | The higher of 1.05 times the average closing price for the month preceding the month containing the allotment date or the closing price on the allotment date. Adjustment provisions apply in the event of a share split, share consolidation or similar event. The floor is Not disclosed. |
| Exercise period | Start Date 21 August 2028 / End date 18 August 2033 |
| Number of Stock Acquisition Rights | Total number issued 2,545 rights (planned allotment; the number may decrease if applications are not made or for other reasons) / Unexercised balance Not disclosed |
| Conditions for lifting transfer restrictions | The transfer, pledging or any other disposition of the share subscription rights is prohibited. As a general rule, the holder must hold a position as a director, audit & supervisory board member, executive officer or employee of the Company or one of its subsidiaries at the time of exercise. |
| Reason for acquisition without consideration | If a proposal concerning a merger, company split, share exchange, share transfer, conversion into a company with transfer restrictions or similar transaction is approved at a shareholders meeting, or by resolution of the Board of Directors where a shareholders meeting resolution is not required, the Company may acquire the share subscription rights without consideration on a date designated by the Company's Board of Directors. |
| Categories and Number of Persons Covered | The Company's executive officers and employees: 415 people, 2,545 rights |
| Procedures under the Corporate Code of Conduct | Resolved at the Board of Directors meeting held on 15 July 2026. Not disclosed whether an opinion was obtained from an independent third party or whether shareholder intentions were confirmed. |
Items this document does not state (16)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateDilution RateTotal number of issued sharesTransfer restriction periodTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To further strengthen the linkage between the Company's performance and its share value, and to enhance the motivation and morale of its executive officers and employees to contribute to improved medium- to long-term performance and increased corporate value.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.